| 000 | 01667 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250514213002.0 | ||
| 264 | 0 | _c20050608 | |
| 008 | 200506s 0 0 eng d | ||
| 022 | _a0098-6577 | ||
| 024 | 7 |
_a10.1111/j.1523-1755.2005.09312.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPalmer, Andrew J | |
| 245 | 0 | 0 |
_aIrbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria. _h[electronic resource] |
| 260 |
_bKidney international. Supplement _cJan 2005 |
||
| 300 |
_aS52-4 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAlbuminuria _xeconomics |
| 650 | 0 | 4 |
_aAntihypertensive Agents _xeconomics |
| 650 | 0 | 4 |
_aBiphenyl Compounds _xeconomics |
| 650 | 0 | 4 |
_aBlood Pressure _xphysiology |
| 650 | 0 | 4 | _aCost Savings |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypertension _xdrug therapy |
| 650 | 0 | 4 | _aIrbesartan |
| 650 | 0 | 4 | _aLife Expectancy |
| 650 | 0 | 4 | _aMarkov Chains |
| 650 | 0 | 4 |
_aSpain _xepidemiology |
| 650 | 0 | 4 |
_aTetrazoles _xeconomics |
| 700 | 1 | _aAnnemans, Lieven | |
| 700 | 1 | _aRoze, Stéphane | |
| 700 | 1 | _aLapuerta, Pablo | |
| 700 | 1 | _aChen, Roland | |
| 700 | 1 | _aGabriel, Sylvie | |
| 700 | 1 | _aCarita, Paulo | |
| 700 | 1 | _aRodby, Roger A | |
| 700 | 1 | _ade Zeeuw, Dick | |
| 700 | 1 | _aParving, Hans-Henrik | |
| 700 | 1 | _aDe Alvaro, Fernando | |
| 773 | 0 |
_tKidney international. Supplement _gno. 93 _gp. S52-4 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1523-1755.2005.09312.x _zAvailable from publisher's website |
| 999 |
_c15294685 _d15294685 |
||